Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Inhibition of SOX15 Sensitizes Esophageal Squamous Carcinoma Cells to Paclitaxel

Author(s): Ming Zhang, Jianying Wang, Tianwei Gao, Xin Chen, Yan Xu, Xiaoting Yu, Xianyang Guo, Rong Zhuang, Ziwei Li, Hongjin Wu* and Juehua Yu*

Volume 19, Issue 5, 2019

Page: [349 - 356] Pages: 8

DOI: 10.2174/1566524019666190405121139

Price: $65

Abstract

Background: SOX15 is a crucial transcription factor involved in the regulation of embryonic development and in the cell fate determination. It is also an important mediator of tumorigenesis in cancer.

Methods: Here, we sought to explore the expression patterns and biological functions of SOX15 in esophageal squamous cell carcinomas (ESCC). SOX15 was found aberrantly overexpressed in ESCC tumors.

Results: Experimentally, inhibition of SOX15 through RNAi suppressed cell proliferation in ESCC cells and sensitized cancer cells to paclitaxel, but not to Cisplatin. Moreover, inhibition of SOX15 significantly repressed the expression of genes associated with WNT and NOTCH signaling pathways, which may contribute to the increased sensitivity to paclitaxel.

Conclusion: In conclusion, the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC.

Keywords: SOX15, ESCC, Paclitaxel, RNAi, WNT, NOTCH.

« Previous Next »
[1]
Wei WQ, Yang J, Zhang SW, Chen WQ, Qiao YL. Esophageal cancer mortality trends during the last 30 years in high risk areas in China: comparison of results from national death surveys conducted in the 1970‘s, 1990’s and 2004-2005. Asian Pac J Cancer Prev 2011; 12(7): 1821-6.
[2]
Song QK, Li J, Jiang HD, He YM, Zhou XQ, Huang CY. Esophageal cancer mortality during 2004-2009 in Yanting County, China. Asian Pac J Cancer Prev 2012; 13(10): 5003-6.
[3]
Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women's H, Broad I, et al Integrated genomic characterization of oesophageal carcinoma. Nature 2017; 541(7636): 169-75.
[4]
Hu N, Kadota M, Liu H, et al. Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer. Cancer Res 2016; 76(7): 1714-23.
[5]
Kalatskaya I. Overview of major molecular alterations during progression from Barrett’s esophagus to esophageal adenocarcinoma. Annals of the New York Academy of Sciences 2016; 1381(1): 74-91.
[6]
Sasaki Y, Tamura M, Koyama R, Nakagaki T, Adachi Y, Tokino T. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol 2016; 22(7): 2284-93.
[7]
Kotecki N, Hiret S, Etienne PL, et al. First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology 2016; 90(2): 88-96.
[8]
Lagergren J, Lagergren P. Oesophageal cancer. BMJ 2010; 341: c6280.
[9]
Lee HJ, Goring W, Ochs M, et al. Sox15 is required for skeletal muscle regeneration. Mol Cell Biol 2004; 24(19): 8428-36.
[10]
Sarraj MA, Wilmore HP, McClive PJ, Sinclair AH. Sox15 is up regulated in the embryonic mouse testis. Gene Expr Patterns 2003; 3(4): 413-7.
[11]
Beranger F, Mejean C, Moniot B, Berta P, Vandromme M. Muscle differentiation is antagonized by SOX15, a new member of the SOX protein family. J Biol Chem 2000; 275(21): 16103-9.
[12]
Moradi A, Ghasemi F, Anvari K, et al. The cross-regulation between SOX15 and Wnt signaling pathway. J Cell Physiol 2017; 232(12): 3221-5.
[13]
Thu KL, Radulovich N, Becker-Santos DD, et al. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling. Oncogene 2014; 33(3): 279-88.
[14]
Sulahian R, Chen J, Arany Z, et al. SOX15 governs transcription in human stratified epithelia and a subset of esophageal adenocarcinomas Cell Mol Gastroenterol Hepatol. 2015; 1(6): 598-609 e6..
[15]
Guo F, Yan L, Guo H, et al. The transcriptome and DNA methylome landscapes of human primordial germ cells. Cell 2015; 161(6): 1437-52.
[16]
Xie SL, Fan S, Zhang SY, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/beta-catenin pathway. Int J Cancer 2018; 142(6): 1252-65.
[17]
Kolenda J, Jensen SS, Aaberg-Jessen C, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 2011; 103(1): 43-58.
[18]
Garros-Regulez L, Aldaz P, Arrizabalaga O, et al. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets 2016; 20(4): 393-405.
[19]
Chikazawa N, Tanaka H, Tasaka T, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30(6): 2041-8.
[20]
Flores ML, Castilla C, Gasca J, et al. Loss of PKCdelta Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/beta-Catenin Pathway and Mcl-1 Accumulation. Mol Cancer Ther 2016; 15(7): 1713-25.
[21]
Zhang K, Song H, Yang P, et al. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling. Cell Prolif 2015; 48(2): 249-58.
[22]
Fischer MM, Cancilla B, Yeung VP, et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv 2017; 3(6): e1700090.
[23]
Kang H, Jeong JY, Song JY, et al. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells. Mol Carcinog 2016; 55(7): 1196-209.
[24]
Wang Z, Li Y, Ahmad A, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806(2): 258-67.
[25]
Rahman MT, Nakayama K, Rahman M, et al. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol 2012; 138(4): 535-44.

Rights & Permissions Print Cite
Article Metrics
38
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy